Intracameral antibiotic injections decreased the risk for postoperative endophthalmitis after cataract surgery by 22-fold when compared with standard topical antibiotic drops in a new ecological ...

Please provide your email address to receive an email when new articles are posted on . Inflammation is a common but treatable complication of cataract surgery. While surgeons have tools to handle ...

A regimen that spares patients recovering from cataract surgery the burden of using antibacterial and anti-inflammatory eye drops several times a day for weeks and instead uses an injection to ...

Please provide your email address to receive an email when new articles are posted on . Central retinal thickness and macular volume increased at 2 months postop but returned to preop levels at 6 ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...

88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study of the ...

Regeneron Pharmaceuticals has announced the U.S. FDA's acceptance for Priority Review of the supplemental Biologics License Application for EYLEA HD (aflibercept) Injection 8 mg, which, if approved, ...

Regeneron presents real-world data on EYLEA HD's effectiveness and economic benefits in treating retinal diseases at ARVO 2025. Regeneron Pharmaceuticals announced the upcoming presentation of data on ...

TARRYTOWN, N.Y., Oct. 21, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for EYLEA ® ...